BHWM
SPRO icon

Beaird Harris Wealth Management’s Spero Therapeutics SPRO Stock Holding History

Beaird Harris Wealth Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-202
Closed -$245 – 620
2023
Q3 		$245 Hold
202
– – ﹤0.01% 427
2023
Q2 		$293 Hold
202
– – ﹤0.01% 432
2023
Q1 		$293 Hold
202
– – ﹤0.01% 454
2022
Q4 		$349 Sell
202
-80
-28% -$149 ﹤0.01% 714
2022
Q3 		$1K Hold
282
– – ﹤0.01% 461
2022
Q2 		$0 Hold
282
– – ﹤0.01% 583
2022
Q1 		$2K Hold
282
– – ﹤0.01% 534
2021
Q4 		$5K Buy
+282
New +$4.48K ﹤0.01% 476

Other funds holding SPRO

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Beaird Harris Wealth Management's SPRO Position: Q4 2023 in Review

Beaird Harris Wealth Management sold out of Spero Therapeutics (SPRO) in Q4 2023, closing a stake of 202 shares — an estimated $245 sold.

Beaird Harris Wealth Management first reported a position in SPRO in Q4 2021 and held it in 8 quarters. The position peaked at $5K in Q4 2021. 50 funds tracked by Wall St. Rank hold SPRO as of Q4 2023.

  • Beaird Harris Wealth Management reported no remaining Spero Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Beaird Harris Wealth Management sold 202 Spero Therapeutics shares in Q4 2023, an estimated $245.
  • Beaird Harris Wealth Management first reported a position in Spero Therapeutics in Q4 2021 and held it in 8 quarters.
  • Beaird Harris Wealth Management's Spero Therapeutics position peaked at $5K in Q4 2021.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2023.

Based on Beaird Harris Wealth Management's 13F filing for Q4 2023, filed 27 Feb 2024.